Company Active LTD

Company profile

Conserv Bioscience Limited

Conserv Bioscience Limited is a UK company with status active founded in 2020.

CRN
12930143
Founded
2020
Age
5

Overview

Legal name
CONSERV BIOSCIENCE LIMITED
Region
Unknown
Registered address
4TH FLOOR, SILVERSTREAM HOUSE,
FITZROY STREET
LONDON
ENGLAND
W1T 6EB
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Conserv Bioscience Limited
CRN 12930143
2
Direct and ultimate controller Active LTD
Peptcell Limited
CRN 04983543

Company events

Reference milestones and recent Companies House filing stream events.

7 events
18 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

04 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

04 Oct
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzODQxODQwNmFkaXF6a2N4

Published 04 Oct 2024 10:36

11 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNTI2NzkzMGFkaXF6a2N4

Published 11 Sep 2024 10:25

05 Oct
2020

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2022
Funded years
2022, 2023, 2024
Age at first award
1 years

Projects

2024 EU-Funded Lead participant

Development and characterization of a pan-flavivirus vaccine candidate

1 Jan 2024 to 31 Dec 2027

Awarded
£266,523
Total cost £266,523

Dengue, yellow fever, Zika, and West Nile viruses are mosquito-borne flaviviruses and global public health burdens that infect half a billion people annually, causing 250,000 deaths, and threaten nearly the entire human population. In a context of human-driven global changes, these threats will intensify with larger and more frequent epidemics, potentiall...

2023 Small Business Research Initiative Lead participant

UNICOR-v, a pancoronavirus vaccine

1 Oct 2023 to 30 Sep 2025

Awarded
£975,768
Total cost £975,768

Coronaviruses are a family of viruses that can infect mammals and birds. As exemplified with SARS, MERS and COVID-19, viruses that infect animals can sometimes infect humans and because we have no preexisting exposure to them, this can lead to epidemics or pandemics. In many low- and-middle-income countries (LMICs) humans live near animals and the infrast...

2023 Small Business Research Initiative Lead participant

A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.

1 Oct 2023 to 30 Sep 2025

Awarded
£680,034
Total cost £680,034

Zika and chikungunya are mosquito-borne viruses with epidemic potential, and both are transmitted by the bite of infected _Aedes_ female mosquitoes. Zika and chikungunya outbreaks have been reported in South and Central America, the Caribbean, the Pacific islands, Africa, and Asia. There is a risk that these viruses will spread geographically by infected ...

2022 Small Business Research Initiative Lead participant

Pan-coronavirus vaccine

1 Apr 2022 to 31 Mar 2023

Awarded
£415,262
Total cost £415,262

Coronaviruses are a family of viruses that can infect mammals and birds. As has happened with SARS, MERS and Covid-19, viruses that infect animals can sometimes jump to infect humans and because humans have no protection against them, this can lead to epidemics or pandemics. In many low-and middle-income countries (LMICs) humans live in close proximity to...

Product types

EU-Funded Small Business Research Initiative